FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
Subscribe To Our Newsletter & Stay Updated